Form 4: Nuvation Bio Director Granted Stock Options Valued at $2.03 Per Share

Nuvation Bio Inc. Director William Anthony Vernon was granted 292,983 stock options with an exercise price of $2.03 per share, set to vest on the earlier of May 21, 2025, or the next shareholder annual meeting.

Summary

• William Anthony Vernon, a Director at Nuvation Bio Inc. (NUVB), was granted 292,983 stock options.
• The options have an exercise price of $2.03 per share.
• The grant date for these options was May 21, 2025.
• The options are set to expire on May 20, 2035.
• 100% of the shares subject to the option will vest on the earlier of the one-year anniversary of the grant date (May 21, 2025) or the next shareholder annual meeting, contingent on Mr. Vernon's continuous service.
• Following this transaction, Mr. Vernon beneficially owns 292,983 derivative securities (stock options) directly.
• The filing was signed by Stephen Dang, Attorney-in-Fact, on May 23, 2025, under a Power of Attorney dated March 19, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 primarily reports a transaction, the grant of options to a director is a standard practice that aligns interests and incentivizes performance, which is generally viewed favorably. There are no negative implications from this specific filing.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedule encourages the director's continued service to the company.

Negatives

• No direct negatives are apparent from this specific Form 4 filing, which primarily reports a compensation event.

Risks

• The value of the stock options is subject to the future performance of Nuvation Bio Inc.'s stock price; if the stock price does not exceed the exercise price, the options may not be valuable.
• The vesting of options is contingent on the director's continuous service, posing a risk if service is terminated before vesting.

Future Outlook

The stock options granted to Director William Anthony Vernon are structured to vest on the earlier of May 21, 2025, or the next shareholder annual meeting, subject to his continuous service, indicating a future alignment of interests and potential future exercise of these options.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company's stock.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, including those in the biotechnology sector like Nuvation Bio Inc.
• The vesting schedule, which includes a one-year anniversary or next annual meeting clause, is typical for director equity grants, aiming to ensure continued commitment.
• The exercise price of $2.03, being the market price on the grant date, is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of 292,983 stock options to William Anthony Vernon, a Director of Nuvation Bio Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised in the future, but it also aims to align the director's interests with shareholder value creation.
• Director (William Anthony Vernon): Directly benefits from the potential future value of the stock options, contingent on company performance and continued service.

Next Steps

• The stock options granted to William Anthony Vernon are expected to vest on the earlier of May 21, 2025, or the next shareholder annual meeting, provided his continuous service.

Key Dates

Keywords

Nuvation Bio Inc., NUVB, Form 4, SEC filing, stock options, director compensation, beneficial ownership, equity grant, insider transaction, vesting schedule